<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512469313</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512469313</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Commentaries</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Discussion of ‘Small-sample behavior of novel phase I cancer trial designs’ by Assaf P Oron and Peter D Hoff</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Carlin</surname><given-names>Bradley P</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512469313">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhong</surname><given-names>Wei</given-names></name>
<xref ref-type="aff" rid="aff2-1740774512469313">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Koopmeiners</surname><given-names>Joseph S</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512469313">a</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512469313"><label>a</label>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA</aff>
<aff id="aff2-1740774512469313"><label>b</label>Department of Biostatistics, Genentech, Inc., South San Francisco, CA, USA</aff>
<author-notes>
<corresp id="corresp1-1740774512469313">Bradley P Carlin, Division of Biostatistics, School of Public Health, University of Minnesota, 420 Delaware Street S.E., Minneapolis, MN 55455, USA. Email: <email>brad@biostat.umn.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>1</issue>
<fpage>81</fpage>
<lpage>85</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Congratulations to the authors on a fine and comprehensive article! The authors have uncovered an important drawback of the standard continual reassessment method (CRM) and related Bayesian phase I (BP1) trials, namely, that they can be ‘sticky’ in their dose allocation schemes, suffering from what the authors call ‘long memory’ (LM). This is the point made by the <inline-formula id="inline-formula1-1740774512469313"><mml:math display="inline" id="math1-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> distributions, shown in Figures 5 to 7, which demonstrate that while the BP1 methods typically perform best on average (a common selling point for their use), they also tend to feature disconcertingly high trial-to-trial variability. Indeed, these figures are reminiscent of decision theory settings wherein a low-variance but biased estimator may actually be preferable to an unbiased one whose variance is much higher. It is unusual to find a commonly used Bayesian method (like BP1) on the wrong side of such an argument, so the article’s findings are worthy of praise and further discussion.</p>
<p>We do however wish to make two points on behalf of BP1 methods, which may serve to ‘rehabilitate’ them to some extent. First, like all Bayesian approaches, BP1 methods do rely on the ‘good model’ assumption, that is, the notion that if the underlying statistical model is far from the truth, all bets for optimality of the procedure are off. Some of the authors’ illustrations (most notably the disconcerting Neuenschwander <italic>et al</italic>. example) suffer from exactly this problem: laboring under an overly simple (e.g., a one-parameter logistic) dose–response model and a weakly informative prior, there is little chance that early maximum tolerated dose (MTD) estimates will be accurate. Safety constraints added under the ‘modified CRM’ rubric of Goodman <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr1-1740774512469313">1</xref>] and others, such as starting at the lowest possible dose and never skipping dose levels when escalating or deescalating, can also significantly alter BP1 operating characteristics. Practical concerns can lead to even more ad hoc fixes, such as the decision in Neuenschwander <italic>et al</italic>. to escalate from <inline-formula id="inline-formula2-1740774512469313"><mml:math display="inline" id="math2-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to <inline-formula id="inline-formula3-1740774512469313"><mml:math display="inline" id="math3-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> (rather than the recommended <inline-formula id="inline-formula4-1740774512469313"><mml:math display="inline" id="math4-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>), which can in turn have odd consequences down the line (here, the apparently ‘incoherent’ decision to further escalate to <inline-formula id="inline-formula5-1740774512469313"><mml:math display="inline" id="math5-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> after seeing two toxicities, when in fact this is a drop from the originally recommended <inline-formula id="inline-formula6-1740774512469313"><mml:math display="inline" id="math6-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>). To us, the repairs actually applied to this design (enriching the model to a two-parameter logistic and increasing the toxicity penalty) all seem quite reasonable, enabling the trial to end successfully and without an overly high dose-limiting toxicity (DLT) rate. Indeed, we would argue that the ability of Bayesian methods to flexibly adapt to this challenge should be viewed as an advantage.</p>
<p>To summarize our first point then, all Bayesian methods (including BP1) are model based and can thus be expected to pay dividends <italic>when the model is at least approximately correct</italic>. They also offer the chance to learn about model flaws as we go, and thence to take corrective action. Indeed, the most standard Bayesian textbooks (e.g., Gelman <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr2-1740774512469313">2</xref>] and Carlin and Louis [<xref ref-type="bibr" rid="bibr3-1740774512469313">3</xref>]) routinely recommend extensive model checking and comparison, and so the uncritical use of simple one-parameter CRM models is indeed to be eyed warily. In the context of BP1 design, Yin and Yuan [<xref ref-type="bibr" rid="bibr4-1740774512469313">4</xref>] use Bayesian model averaging across multiple parallel CRM models, each with a different toxicity probability ‘skeleton’, thus incorporating Bayesian model choice into a phase I trial. But even when using only the standard CRM, the use of three-patient (not one-patient) cohorts, better priors (including that on which starting dose to select), and the modified CRM restrictions are all simple and sensible in practice. Discovering problems with our statistical model should not in our view make us want to abandon modeling entirely, as up-and-down and related 3 + 3 methods do. Instead, it should make us want to build a better model, where we remember that ‘model’ includes the dose–response curve, the error distribution, the prior distribution, and so on. Up-and-down methods utilize some of the same external information (e.g., imposing inequality constraints via a separate, post hoc isotonic regression analysis), but do so in an ad hoc, one-step-at-a-time fashion, thus precluding accurate propagation of all sources of uncertainty throughout the analysis. The authors seem to view the fully Bayesian approach as guilty of making an ‘unrealistic promise’ here and seek to retreat to the safer ground of older methods useful for ‘dose selection only’. But surely, point and interval estimation of the MTD <italic>is</italic> the primary goal of many phase I investigators, so, armed as we are with loads of models, computational methods, expert information, published literature reviews, and a small sample of current binary observations, retreat seems premature.</p>
<p>Our reluctance to retreat from modeling brings us to our second point, which is the authors’ contention that the ‘overarching feature’ of BP1 methods is their ‘insistence upon treating every cohort with the estimated MTD at any given time’. While one might well get this impression from reading the existing BP1 literature (or the summary in Chapter 3 of the recent textbook by Berry <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr5-1740774512469313">5</xref>]), it is not our opinion that this feature is crucial to a principled BP1 modeling approach. Indeed, the main message we take from the authors’ study is that while it may be perfectly sensible to use the Likelihood Principle (LP) for <italic>estimation</italic> (as when using the posterior mean as our final MTD estimate), making it do double duty as a <italic>design</italic> principle (as BP1 methods do when using the current posterior to choose the next dose) may not be: the authors show that this can lead to designs with long memory properties that biostatisticians and clinicians may well find undesirable.</p>
<p>To remedy this, we might simply <italic>sample</italic> the next dose from the MTD posterior distribution, instead of just using its mean. This would undoubtedly reduce ‘settling’ in the MTD trajectories as well as lighten the tails of the trial-to-trial <inline-formula id="inline-formula7-1740774512469313"><mml:math display="inline" id="math7-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> distributions, but the corresponding dosing schedules would likely be too erratic to satisfy many clinicians. As a less drastic alternative, we might limit the memory of our BP1 procedure by utilizing only the data from the <inline-formula id="inline-formula8-1740774512469313"><mml:math display="inline" id="math8-1740774512469313"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:math></inline-formula> most recent cohorts, <inline-formula id="inline-formula9-1740774512469313"><mml:math display="inline" id="math9-1740774512469313"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, when determining the next dose. Reminiscent of temporally adaptive escalation with overdose control (EWOC) approaches, we might allow <inline-formula id="inline-formula10-1740774512469313"><mml:math display="inline" id="math10-1740774512469313"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:math></inline-formula> to increase as the trial wears on, with <inline-formula id="inline-formula11-1740774512469313"><mml:math display="inline" id="math11-1740774512469313"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:math></inline-formula> approaching the total number of cohorts <inline-formula id="inline-formula12-1740774512469313"><mml:math display="inline" id="math12-1740774512469313"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> as our final MTD estimate becomes sufficiently precise. In our view, this does not violate the LP, since we only limit the Bayesian procedure’s memory at the interim allocation stage, not at the final estimation stage.</p>
<p>We offer a brief investigation of this approach in the context of a standard CRM using a one-parameter logistic dose–response curve</p>
<p>
<disp-formula id="disp-formula1-1740774512469313">
<label>(1)</label>
<mml:math display="block" id="math13-1740774512469313">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>α</mml:mi>
<mml:mo>+</mml:mo>
<mml:mi>β</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>α</mml:mi>
<mml:mo>+</mml:mo>
<mml:mi>β</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774512469313" xlink:href="10.1177_1740774512469313-eq1.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula13-1740774512469313"><mml:math display="inline" id="math14-1740774512469313"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> indexes the <inline-formula id="inline-formula14-1740774512469313"><mml:math display="inline" id="math15-1740774512469313"><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:math></inline-formula> possible dose levels <inline-formula id="inline-formula15-1740774512469313"><mml:math display="inline" id="math16-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:math></inline-formula>. We fix <inline-formula id="inline-formula16-1740774512469313"><mml:math display="inline" id="math17-1740774512469313"><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:math></inline-formula> at −3 and assume <inline-formula id="inline-formula17-1740774512469313"><mml:math display="inline" id="math18-1740774512469313"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:math></inline-formula> follows an exponential distribution with mean 1. We also investigate an alternative, nonparametric model that avoids any smooth baseline link entirely, and instead assumes only that <inline-formula id="inline-formula18-1740774512469313"><mml:math display="inline" id="math19-1740774512469313"><mml:mrow><mml:mn>0</mml:mn><mml:mspace width="0.25em"/><mml:mo>≤</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>&lt;</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>&lt;</mml:mo><mml:mo>⋯</mml:mo><mml:mspace width="0.25em"/><mml:mo>&lt;</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. To implement this nonparametric isotonic regression in a fully Bayesian fashion, a simple solution is to add these constraints to an otherwise vague prior. For example, taking <inline-formula id="inline-formula19-1740774512469313"><mml:math display="inline" id="math20-1740774512469313"><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula>, we can set <inline-formula id="inline-formula20-1740774512469313"><mml:math display="inline" id="math21-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula21-1740774512469313"><mml:math display="inline" id="math22-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula22-1740774512469313"><mml:math display="inline" id="math23-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula23-1740774512469313"><mml:math display="inline" id="math24-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula24-1740774512469313"><mml:math display="inline" id="math25-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, and <inline-formula id="inline-formula25-1740774512469313"><mml:math display="inline" id="math26-1740774512469313"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, where <inline-formula id="inline-formula26-1740774512469313"><mml:math display="inline" id="math27-1740774512469313"><mml:mrow><mml:mi>Unif</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> denotes the uniform distribution on the interval <inline-formula id="inline-formula27-1740774512469313"><mml:math display="inline" id="math28-1740774512469313"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Such a nonparametric uniform prior (NUP) model is readily implemented in BUGS or JAGS, and should perform well when the number of dose levels is not too large.</p>
<p>After each look at the data, we update the memory-limited posterior means <inline-formula id="inline-formula28-1740774512469313"><mml:math display="inline" id="math29-1740774512469313"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></inline-formula> and then select as our next dose the one that minimizes the distance</p>
<p>
<disp-formula id="disp-formula2-1740774512469313">
<label>(2)</label>
<mml:math display="block" id="math30-1740774512469313">
<mml:mrow>
<mml:mi>dis</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>|</mml:mo>
<mml:mi>E</mml:mi>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>Y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>|</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-1740774512469313" xlink:href="10.1177_1740774512469313-eq2.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula29-1740774512469313"><mml:math display="inline" id="math31-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is our physician-specified target rate of toxicity. In this simple illustration, we do not permit early stopping, simply running all trials to the maximum sample size. Our simulation assumes that the patient recruitment plan is to enroll a new cohort of size <inline-formula id="inline-formula30-1740774512469313"><mml:math display="inline" id="math32-1740774512469313"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula> every 6 weeks, with all toxicity outcome data from each cohort assumed available prior to the enrollment of the next cohort. For this illustration, we take <inline-formula id="inline-formula31-1740774512469313"><mml:math display="inline" id="math33-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>36</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="inline-formula32-1740774512469313"><mml:math display="inline" id="math34-1740774512469313"><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula>, and set the maximum number of cohorts <inline-formula id="inline-formula33-1740774512469313"><mml:math display="inline" id="math35-1740774512469313"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:math></inline-formula>. Here, we compare our logistic and NUP models as implemented using standard CRM rules (where the full interim dataset <inline-formula id="inline-formula34-1740774512469313"><mml:math display="inline" id="math36-1740774512469313"><mml:mrow><mml:mi>Y</mml:mi></mml:mrow></mml:math></inline-formula> is used for dose allocation) to our ‘short memory’ version (where only <inline-formula id="inline-formula35-1740774512469313"><mml:math display="inline" id="math37-1740774512469313"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> is used for this purpose).</p>
<p>We present simulation results in the case where the optimal dose is Dose 4; entries for this dose are highlighted in boldface in the tables for easier identification. We used R2jags (<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/R2jags">cran.r-project.org/web/packages/R2jags</ext-link>) to call JAGS (mcmc-jags.sourceforge.net) from R version 2.12.2. Each of our simulation studies used 1000 simulated trials, analyzed by generating two Markov chain Monte Carlo (MCMC) chains run for 5000 iterations following a 5000-iteration burn-in period. Random manual checks revealed no significant MCMC convergence issues using standard convergence diagnostics.</p>
<p>
<xref ref-type="table" rid="table1-1740774512469313">Table 1</xref> shows the true parameter settings in our first scenario, for which the simple one-parameter logistic function can describe the true probability of toxicity reasonably well. <xref ref-type="fig" rid="fig1-1740774512469313">Figure 1</xref> provides histograms of trial-to-trial variability in <inline-formula id="inline-formula36-1740774512469313"><mml:math display="inline" id="math38-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> similar to those in the authors’ Figure 5. The first row shows the empirical distributions of <inline-formula id="inline-formula37-1740774512469313"><mml:math display="inline" id="math39-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for the standard, long memory (LM) CRM, while the second row shows the short-memory (SM) results. The first column adopts the logistic model (which is the truth here), while the second column utilizes the more flexible NUP model. The results confirm that our SM approach does indeed reduce the undesirable heavy tail behavior in the <inline-formula id="inline-formula38-1740774512469313"><mml:math display="inline" id="math40-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> distribution. However, these gains do come at the price of a small reduction (approximately 1 cohort) in <inline-formula id="inline-formula39-1740774512469313"><mml:math display="inline" id="math41-1740774512469313"><mml:mrow><mml:mover><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, marked as in the authors’ figures by vertical lines. <xref ref-type="table" rid="table2-1740774512469313">Table 2</xref> investigates this trade-off a bit further by showing the empirical selection probabilities and percents of patients treated at each dose using the competing parametric and nonparametric link functions in both the LM and SM cases. This table also confirms that our memory-limited CRM continues to perform nearly identically to the standard CRM with respect to these criteria.</p>
<table-wrap id="table1-1740774512469313" position="float">
<label>Table 1.</label>
<caption>
<p>Simulation parameter settings when Dose 4 is optimal and a simple logistic function can readily fit the true probability of toxicity</p>
</caption>
<graphic alternate-form-of="table1-1740774512469313" xlink:href="10.1177_1740774512469313-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Dose</th>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">
<inline-formula id="inline-formula40-1740774512469313">
<mml:math display="inline" id="math42-1740774512469313">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">5</th>
<th align="left">6</th>
</tr>
</thead>
<tbody>
<tr>
<td>True <inline-formula id="inline-formula41-1740774512469313"><mml:math display="inline" id="math43-1740774512469313"><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:math></inline-formula></td>
<td>0.07</td>
<td>0.13</td>
<td>0.23</td>
<td><bold>0.36</bold></td>
<td>0.5</td>
<td>0.61</td>
</tr>
<tr>
<td>True distance</td>
<td>0.29</td>
<td>0.23</td>
<td>0.13</td>
<td><bold>0</bold></td>
<td>0.14</td>
<td>0.25</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig1-1740774512469313" position="float">
<label>Figure 1.</label>
<caption>
<p>Between-run variability in <inline-formula id="inline-formula42-1740774512469313"><mml:math display="inline" id="math44-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, the number of cohorts allocated to the MTD, for the long-memory and short-memory versions of the logistic and NUP models in the logistic scenario. The runs were 16 cohorts long with cohort size of 3.</p>
<p>NUP: nonparametric uniform prior; MTD: maximum tolerated dose; SD: standard deviation.</p>
</caption>
<graphic xlink:href="10.1177_1740774512469313-fig1.tif"/>
</fig>
<table-wrap id="table2-1740774512469313" position="float">
<label>Table 2.</label>
<caption>
<p>Operating characteristics of the logistic and nonparametric uniform prior (NUP) models under long memory (LM) and short memory (SM) when Dose 4 is optimal and a simple logistic function can readily fit the true probability of toxicity</p>
</caption>
<graphic alternate-form-of="table2-1740774512469313" xlink:href="10.1177_1740774512469313-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model (memory)</th>
<th align="left">Operating characteristics</th>
<th align="left" colspan="6">Dose<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">
<inline-formula id="inline-formula43-1740774512469313">
<mml:math display="inline" id="math45-1740774512469313">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">5</th>
<th align="left">6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Logistic (LM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0.005</td>
<td>0.206</td>
<td><bold>0.627</bold></td>
<td>0.152</td>
<td>0.01</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.066</td>
<td>0.095</td>
<td>0.245</td>
<td><bold>0.387</bold></td>
<td>0.162</td>
<td>0.045</td>
</tr>
<tr>
<td>Logistic (SM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0.002</td>
<td>0.170</td>
<td><bold>0.632</bold></td>
<td>0.189</td>
<td>0.007</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.067</td>
<td>0.097</td>
<td>0.249</td>
<td><bold>0.332</bold></td>
<td>0.187</td>
<td>0.068</td>
</tr>
<tr>
<td>NUP (LM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0.004</td>
<td>0.403</td>
<td><bold>0.585</bold></td>
<td>0.008</td>
<td>0</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.063</td>
<td>0.096</td>
<td>0.471</td>
<td><bold>0.363</bold></td>
<td>0.007</td>
<td>0</td>
</tr>
<tr>
<td>NUP (SM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0.002</td>
<td>0.366</td>
<td><bold>0.618</bold></td>
<td>0.014</td>
<td>0</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.063</td>
<td>0.106</td>
<td>0.530</td>
<td><bold>0.297</bold></td>
<td>0.004</td>
<td>0</td>
</tr>
</tbody>
</table>
</table-wrap>
<p><xref ref-type="table" rid="table3-1740774512469313">Table 3</xref> describes a second, unsmooth scenario, in which no logistic function can readily approximate the true probability of toxicity due to the large jump between Doses 3 and 4. Histograms showing trial-to-trial variability in <inline-formula id="inline-formula44-1740774512469313"><mml:math display="inline" id="math46-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> for this scenario appear in <xref ref-type="fig" rid="fig2-1740774512469313">Figure 2</xref>, while the corresponding selection probabilities and proportions of patients treated at each dose appear in <xref ref-type="table" rid="table4-1740774512469313">Table 4</xref>. The results indicate the NUP models performed better than the logistic models in this unsmooth scenario. Still, the results confirm that our simple memory-limiting device leads to dramatic improvements in <inline-formula id="inline-formula45-1740774512469313"><mml:math display="inline" id="math47-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> performance while leaving selection probabilities and the proportions of patients treated virtually unchanged. Particularly striking is the second column of <xref ref-type="fig" rid="fig2-1740774512469313">Figure 2</xref>, where the SM BP1 method completely eliminates the bimodality of the LM version while reducing <inline-formula id="inline-formula46-1740774512469313"><mml:math display="inline" id="math48-1740774512469313"><mml:mrow><mml:mover><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> by just 0.5 cohorts.</p>
<table-wrap id="table3-1740774512469313" position="float">
<label>Table 3.</label>
<caption>
<p>Simulation parameter settings when Dose 4 is optimal and an unsmooth scenario where a parametric function cannot readily fit the true probability of toxicity</p>
</caption>
<graphic alternate-form-of="table3-1740774512469313" xlink:href="10.1177_1740774512469313-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Dose</th>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">
<inline-formula id="inline-formula47-1740774512469313">
<mml:math display="inline" id="math49-1740774512469313">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">5</th>
<th align="left">6</th>
</tr>
</thead>
<tbody>
<tr>
<td>True <inline-formula id="inline-formula48-1740774512469313"><mml:math display="inline" id="math50-1740774512469313"><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:math></inline-formula></td>
<td>0.1</td>
<td>0.12</td>
<td>0.2</td>
<td><bold>0.55</bold></td>
<td>0.6</td>
<td>0.62</td>
</tr>
<tr>
<td>True distance</td>
<td>0.45</td>
<td>0.43</td>
<td>0.35</td>
<td><bold>0</bold></td>
<td>0.05</td>
<td>0.07</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig2-1740774512469313" position="float">
<label>Figure 2.</label>
<caption>
<p>Between-run variability in <inline-formula id="inline-formula49-1740774512469313"><mml:math display="inline" id="math51-1740774512469313"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, the number of cohorts allocated to the MTD, for the long-memory and short-memory versions of the logistic and NUP models in the unsmooth scenario. The runs were 16 cohorts long with cohort size of 3.</p>
<p>NUP: nonparametric uniform prior; MTD: maximum tolerated dose; SD: standard deviation.</p>
</caption>
<graphic xlink:href="10.1177_1740774512469313-fig2.tif"/>
</fig>
<table-wrap id="table4-1740774512469313" position="float">
<label>Table 4.</label>
<caption>
<p>Operating characteristics of the logistic and nonparametric uniform prior (NUP) models under long memory (LM) and short memory (SM) when Dose 4 is optimal and a parametric function cannot readily fit the true probability of toxicity</p>
</caption>
<graphic alternate-form-of="table4-1740774512469313" xlink:href="10.1177_1740774512469313-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model (memory)</th>
<th align="left">Operating characteristics</th>
<th align="left" colspan="6">Dose<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">
<inline-formula id="inline-formula50-1740774512469313">
<mml:math display="inline" id="math52-1740774512469313">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">5</th>
<th align="left">6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Logistic (LM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0</td>
<td>0.010</td>
<td><bold>0.465</bold></td>
<td>0.330</td>
<td>0.195</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.063</td>
<td>0.064</td>
<td>0.097</td>
<td><bold>0.364</bold></td>
<td>0.245</td>
<td>0.167</td>
</tr>
<tr>
<td>Logistic (SM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0</td>
<td>0.020</td>
<td><bold>0.457</bold></td>
<td>0.354</td>
<td>0.169</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.063</td>
<td>0.063</td>
<td>0.135</td>
<td><bold>0.335</bold></td>
<td>0.240</td>
<td>0.164</td>
</tr>
<tr>
<td>NUP (LM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0</td>
<td>0.010</td>
<td><bold>0.719</bold></td>
<td>0.266</td>
<td>0.005</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.062</td>
<td>0.063</td>
<td>0.086</td>
<td><bold>0.570</bold></td>
<td>0.215</td>
<td>0.004</td>
</tr>
<tr>
<td>NUP (SM)</td>
<td>Selection probability</td>
<td>0</td>
<td>0</td>
<td>0.005</td>
<td><bold>0.723</bold></td>
<td>0.266</td>
<td>0.006</td>
</tr>
<tr>
<td/>
<td>Proportion of patients treated</td>
<td>0.062</td>
<td>0.063</td>
<td>0.135</td>
<td><bold>0.540</bold></td>
<td>0.196</td>
<td>0.004</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>We note that the potential range of memory-limited BP1 modeling is much broader than investigated here. Potential enhancements include simultaneous models for toxicity and efficacy (or surrogate efficacy), range parameters to capture lower or upper bounds on response probabilities, differential weighting schemes to place a higher penalty on overdosing than underdosing, early termination rules to control overtoxicity and to enable an early decision regarding the optimal dosage, and so on (see Zhong <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr6-1740774512469313">6</xref>] and [<xref ref-type="bibr" rid="bibr7-1740774512469313">7</xref>] for a discussion of some of these issues in the standard BP1 context).</p>
<p>In closing, we again congratulate the authors on their study and look forward to future developments in this surprisingly resilient research area. In particular, we concur with the authors that hybrid methods that attempt to capture the best features of both up-and-down and BP1 approaches may well offer the most sensible path forward.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The study of the first two authors was supported in part by National Cancer Institute (NCI) grant R01-CA095955.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512469313">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodman</surname><given-names>SN</given-names></name>
<name><surname>Zahurak</surname><given-names>ML</given-names></name>
<name><surname>Piantadosi</surname><given-names>S</given-names></name>
</person-group>. <article-title>Some practical improvements in the continual reassessment method for phase I studies</article-title>. <source>Stat Med</source> <year>1995</year>; <volume>14</volume>: <fpage>1149</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr2-1740774512469313">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gelman</surname><given-names>A</given-names></name>
<name><surname>Carlin</surname><given-names>J</given-names></name>
<name><surname>Stern</surname><given-names>H</given-names></name>
<name><surname>Rubin</surname><given-names>DB</given-names></name>
</person-group>. <source>Bayesian Data Analysis</source> (<edition>2nd edn</edition>). <publisher-name>Chapman and Hall/CRC Press</publisher-name>, <publisher-loc>Boca Raton, FL</publisher-loc>, <year>2004</year>.</citation>
</ref>
<ref id="bibr3-1740774512469313">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>Louis</surname><given-names>TA</given-names></name>
</person-group>. <source>Bayesian Methods for Data Analysis</source> (<edition>3rd edn</edition>). <publisher-name>Chapman and Hall/CRC Press</publisher-name>, <publisher-loc>Boca Raton, FL</publisher-loc>, <year>2009</year>.</citation>
</ref>
<ref id="bibr4-1740774512469313">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname><given-names>G</given-names></name>
<name><surname>Yuan</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Bayesian model averaging continual reassessment method in phase I clinical trials</article-title>. <source>J Am Stat Assoc</source> <year>2009</year>; <volume>104</volume>: <fpage>954</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr5-1740774512469313">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Berry</surname><given-names>SM</given-names></name>
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>Lee</surname><given-names>JJ</given-names></name>
<name><surname>Müller</surname><given-names>P</given-names></name>
</person-group>. <source>Bayesian Adaptive Methods for Clinical Trials</source>. <publisher-name>Chapman and Hall/CRC Press</publisher-name>, <publisher-loc>Boca Raton, FL</publisher-loc>, <year>2011</year>.</citation>
</ref>
<ref id="bibr6-1740774512469313">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>W</given-names></name>
<name><surname>Koopmeiners</surname><given-names>JS</given-names></name>
<name><surname>Carlin</surname><given-names>BP</given-names></name>
</person-group>. <article-title>A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy</article-title>. <source>Stat Med</source> <year>2012</year>; <volume>31</volume>: <fpage>3885</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr7-1740774512469313">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>W</given-names></name>
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>Koopmeiners</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials</article-title>. <source>J Stat Theory Pract</source>, in press.</citation>
</ref>
</ref-list>
</back>
</article>